New Insights from Phase 2b Trial at CHEST 2025
PureTech Health plc, a biotherapeutics company renowned for its innovative approaches, has unveiled important findings from its Phase 2b ELEVATE IPF trial, which focuses on the treatment of idiopathic pulmonary fibrosis (IPF) in older adults. The results, presented at the American College of Chest Physicians annual meeting, reveal that the safety and efficacy of deupirfenidone (LYT-100) remain consistent across various age groups, including patients aged 75 and older. Historically, this demographic has been underrepresented in clinical trials and treatment protocols, primarily due to concerns regarding medication tolerability.
The findings suggest that deupirfenidone may bridge a crucial gap in IPF management for older patients, who have often faced barriers to effective treatment. Dr. Tejaswini Kulkarni, an Associate Professor at the University of Alabama at Birmingham, highlighted that the data offers reassurance that advanced age does not inherently lead to a diminished treatment experience. This is particularly significant given that IPF predominantly affects older individuals, many of whom have received inadequate treatment options.
Trial Design and Results
The ELEVATE IPF trial employed a randomized, double-blind, placebo-controlled design, comparing deupirfenidone at doses of 825 mg and 550 mg three times daily against a placebo and pirfenidone (801 mg TID). A crucial aspect of this analysis was the focus on patients aged 75 and older, comprising 91 subjects, in comparison to younger participants under 75 years of age, totaling 166 subjects. Notably, the incidence of treatment-related side effects, particularly gastrointestinal issues, was comparable between the two age groups. For instance, rates of nausea were reported at 18.2% for older patients taking the higher dose of deupirfenidone, slightly lower than the 21.4% rate observed in their younger counterparts.
Furthermore, the efficacy data aligned with previous reports, reinforcing the notion that deupirfenidone maintains its robust effectiveness across different age demographics. Camilla Graham, Senior Vice President of Medical Affairs at PureTech, emphasized that these findings underscore the potential of deupirfenidone to serve as a viable treatment option for a traditionally underserved group of patients.
Understanding Deupirfenidone and IPF
Deupirfenidone (LYT-100), a next-generation antifibrotic medication, is considered a promising candidate for establishing a new standard of care for IPF. The drug is a deuterated version of pirfenidone, one of the few FDA-approved therapies for this debilitating condition. As of 2019, only about 25% of patients diagnosed with IPF in the United States had received treatment, largely due to challenges in tolerating existing antifibrotic medications. Deupirfenidone aims to address these limitations by potentially offering better tolerability without sacrificing efficacy.
IPF is characterized by progressive lung scarring that leads to a gradual decline in lung function, with a median survival rate post-diagnosis ranging from two to five years. This lack of effective treatment options highlights the urgency for new therapies like deupirfenidone, particularly for older populations who are at greater risk.
In conclusion, the promising results from PureTech’s Phase 2b trial not only illuminate the potential of deupirfenidone in treating older IPF patients but also highlight the ongoing need for innovative solutions in managing this challenging disease. As research progresses, deupirfenidone may become a critical part of the therapeutic landscape for IPF, particularly among those who have historically been overlooked.
Related
